Exposure to the nerve agent soman is difficult to treat due to the rapid dealkylation of the soman-acetylcholinesterase (AChE) conjugate known as aging. Oxime antidotes commonly used to reactivate organophosphate inhibited AChE are ineffective against soman, while the efficacy of the recommended nerve agent bioscavenger butyrylcholinesterase is limited by strictly stoichiometric scavenging. To overcome this limitation, we tested ex vivo, in human blood, and in vivo, in soman exposed mice, the capacity of aging-resistant human AChE mutant Y337A/F338A in combination with oxime HI-6 to act as a catalytic bioscavenger of soman. HI-6 was previously shown in vitro to efficiently reactivate this mutant upon soman, as well as VX, cyclosarin, sarin, and paraoxon, inhibition. We here demonstrate that ex vivo, in whole human blood, 1 μM soman was detoxified within 30 min when supplemented with 0.5 μM Y337A/F338A AChE and 100 μM HI-6. This combination was further tested in vivo. Catalytic scavenging of soman in mice improved the therapeutic outcome and resulted in the delayed onset of toxicity symptoms. Furthermore, in a preliminary in vitro screen we identified an even more efficacious oxime than HI-6, in a series of 42 pyridinium aldoximes, and 5 imidazole 2-aldoxime N-propylpyridinium derivatives. One of the later imidazole aldoximes, RS-170B, was a 2-3-fold more effective reactivator of Y337A/F338A AChE than HI-6 due to the smaller imidazole ring, as indicated by computational molecular models, that affords a more productive angle of nucleophilic attack.

†Institute for Medical Research and Occupational Health Ksaverska cesta 2 HR 10000 Zagreb Croatia

‡Skaggs Institute for Chemical Biology and Department of Chemistry The Scripps Research Institute La Jolla California 92037 United States

∥Department of Chemistry Faculty of Science University of Hradec Kralove Rokitanskeho 62 50003 Hradec Kralove Czech Republic

Zobrazit více v PubMed

De Jong LPA, Wolring GZ. Stereospecific reactivation by some Hagedorn-oximes of acetylcholinesterases from various species including man, inhibited by soman. Biochem Pharmacol. 1984;33:1119–1125. PubMed

Shafferman A, Ordentlich A, Barak D, Stein D, Aiel N, Velan B. Aging of phosphylated human acetylcholinesterase: catalytic processes mediated by aromatic and polar residues of the active centre. Biochem J. 1996;318:833–840. PubMed PMC

Barak D, Ordentlich A, Segall Y, Velan B, Benschop HP, De Jong LPA, Shafferman A. Carbocation-mediated processes in biocatalysts: contribution of aromatic moieties. J Am Chem Soc. 1997;119:3157–3158.

Ashani Y, Shapira S, Levy D, Wolfe AD, Doctor BP, Raveh L. Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice. Biochem Pharmacol. 1991;41:37–41. PubMed

Maxwell DM, Brecht KM, Doctor BP, Wolfe AD. Comparison of antidote protection against soman by pyridostigmine, HI-6 and acetylcholinesterase. J Pharmacol Exp Ther. 1993;264:1085–1089. PubMed

Lenz DE, Yeung D, Smith RJ, Sweeney RE, Lumley LA, Cerasoli DM. Stoichiometric and catalytic scavengers as protection against nerve agent toxicity: A mini review. Toxicology. 2007;233:31–39. PubMed

Vučinić S, Zlatković M, Antonijević B, Ćurčić M, Bošković B. Fresh frozen plasma as a successful antidotal supplement in acute organophosphate poisoning. Arh Hig Rada Toksikol. 2013;64:273–277. PubMed

Wille T, Thiermann H, Worek F. In vitro kinetics of nerve agent degradation by fresh frozen plasma (FFP) Arch Toxicol. 2014;88:301–307. PubMed

Kovarik Z, Radić Z, Berman HA, Taylor P. Mutation of acetylcholinesterase to enhance oxime-assisted catalytic turnover of methylphosphonates. Toxicology. 2007;233:79–84. PubMed

Taylor P, Reiner E, Kovarik Z, Radić Z. Application of recombinant DNA methods for production of cholinesterases as organophosphate antidotes and detectors. Arh Hig Rada Toksikol. 2007;58:339–345. PubMed

Nachon F, Brazzolotto X, Trovaslet M, Masson P. Progress in the development of enzyme-based nerve agent bioscavengers. Chem Biol Interact. 2013;206:536–544. PubMed

Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, Dvir H, Ravelli RB, McCarthy A, Toker L, Silman I, Sussman JL, Tawfik DS. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol. 2004;11:412–419. PubMed

Amitai G, Gaidukov L, Adani R, Yishay S, Yacov G, Kushnir M, Teitlboim S, Lindenbaum M, Bel P, Khersonsky O, Tawfik DS, Meshulam H. Enhanced stereoselective hydrolysis of toxic organophosphates by directly evolved variants of mammalian serum paraoxonase. FEBS J. 2006;273:1906–1919. PubMed

diTargiani RC, Chandrasekaran L, Belinskaya T, Saxena A. In search of a catalytic bioscavenger for the prophylaxis of nerve agent toxicity. Chem Biol Interact. 2010;187:349–354. PubMed

Goldsmith M, Ashani Y, Simo Y, Ben-David M, Leader H, Silman I, Sussman JL, Tawfik DS. Evolved stereoselective hydrolases for broad-spectrum G-type nerve agent detoxification. Chem Biol. 2012;19:456–466. PubMed

Melzer M, Heidenreich A, Dorandeu F, Gäb J, Kehe K, Thiermann H, Letzel T, Blum MM. In vitro and in vivo efficacy of PEGylated diisopropyl fluorophosphatase (DFPase) Drug Test Anal. 2012;4:262–270. PubMed

Cochran R, Kalisiak J, Küçükkılınç T, Radić Z, Garcia E, Zhang L, Ho YK, Amitai G, Kovarik Z, Fokin VV, Sharpless KB, Taylor P. Oxime-assisted acetylcholinesterase catalytic scavengers of organophosphates that resist aging. J Biol Chem. 2011;286:29718–29724. PubMed PMC

Sit RK, Fokin VV, Amitai G, Sharpless KB, Taylor P, Radić Z. Imidazole aldoximes effective in assisting butyrylcholinesterase catalysis of organophosphate detoxification. J Med Chem. 2014;57:1378–1389. PubMed PMC

Amitai G, Adani R, Yacov G, Yishay S, Teitlboim S, Tveria L, Limanovich O, Kushnir M, Meshulam H. Asymmetric fluorogenic organophosphates for the development of active organophosphate hydrolases with reversed stereoselectivity. Toxicology. 2007;233:187–198. PubMed

Ellman LG, Courtney DK, Andres V, Featherstone MR. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961;7:88–95. PubMed

Kovarik Z, Bosak A, Šinko G, Latas T. Exploring the active sites of cholinesterases by inhibition with bambuterol and haloxon. Croat Chem Acta. 2003;76:63–67.

Kovarik Z, Maček N, Sit RK, Radić Z, Fokin VV, Sharpless KB, Taylor P. Centrally acting oximes in reactivation of tabun-phosphoramidated AChE. Chem Biol Interact. 2013;203:77–80. PubMed PMC

Kovarik Z, Radić Z, Berman HA, Simeon-Rudolf V, Reiner E, Taylor P. Mutant cholinesterases possessing enhanced capacity for reactivation of their phosphonylated conjugates. Biochemistry. 2004;43:3222–3229. PubMed

Kovarik Z, Čalić M, Šinko G, Bosak A. Structure-activity approach in the reactivation of tabun-phosphorylated human acetylcholinesterase with bispyridinium para-oximes. Arh Hig Rada Toksikol. 2007;58:201–209. PubMed

Thompson WR. Use of moving averages and interpolation to estimate median-effective dose. Bacteriol Rev. 1947;11:115–145. PubMed

Weil CS. Tables for convenient calculation of median-effective dose (LD50 or ED50) and instructions in their use. Biometrics. 1952;8:249–263.

Čalić M, Lucić Vrdoljak A, Radić B, Jelić D, Jun D, Kuča K, Kovarik Z. In vitro and in vivo evaluation of pyridinium oximes: mode of interaction with acetylcholinesterase, effect on tabun- and soman-poisoned mice and their cytotoxicity. Toxicology. 2006;219:85–96. PubMed

Berend S, Katalinić M, Lucić Vrdoljak A, Kovarik Z, Kuča K, Radić B. In vivo experimental approach to treatment against tabun poisoning. J Enzyme Inhib Med Chem. 2010;25:531–536. PubMed

Radić Z, Dale T, Kovarik Z, Berend S, Garcia E, Zhang L, Amitai G, Green C, Radić B, Duggan BM, Ajami D, Rebek J, Taylor P. Catalytic detoxification of nerve agent and pesticide organophosphates by butyrylcholinesterase assisted with non-pyridinium oximes. Biochem J. 2013;450:231–242. PubMed PMC

Munro NB, Ambrose KR, Watson AP. Toxicity of the organophosphate chemical warfare agents GA, GB and VX: implication for public protection. Environ Health Perspect. 1994;102:18–38. PubMed PMC

Masson P, Lockridge O. Butyrylcholinesterase for protection from organophosphorus poisons: catalytic complexities and hysteretic behavior. Arch Biochem Biophys. 2010;494:107–144. PubMed PMC

Bucht G, Puu G. Aging and reactivatability of plaice cholinesterase inhibited by soman and its stereoisomers. Biochem Pharmacol. 1984;33:3573–3577. PubMed

Benschop HP, De Jong LPA. Nerve agent stereoisomers: analysis isolation and toxicology. Acc Chem Res. 1988;21:368–374.

Shih TM, Whalley CE, Valdes JJ. A comparison of cholinergic effects of HI-6 and pralidoxime-2-chloride (2-PAM) in soman poisoning. Toxicol Lett. 1991;55:131–147. PubMed

Bošković B. The treatment of soman poisoning and its perspectives. Fundam Appl Toxicol. 1981;1:203–213. PubMed

Schoene K, Steinhanses J, Oldiges H. Reactivation of soman inhibited acetylcholinesterase in vitro by bispyridinuim-2-aldoximes. Biochem Pharmacol. 1983;32:1649–1651. PubMed

Mazor O, Cohen O, Kronman C, Raveh L, Stein D, Ordentlich A, Shafferman A. Aging-resistant organophosphate bioscavenger based on polyethylene glycol-conjugated F338A human acetylcholinesterase. Mol Pharmacol. 2008;74:755–63. PubMed

Benschop HP, Konings CAG, van Genderen J, De Jong LPA. Isolation, anticholinesterase properties, and acute toxicity in mice of four stereo-isomers of the nerve agent soman. Toxicol Appl Pharmacol. 1984;72:61–74. PubMed

Kovarik Z, Radić Z, Berman HA, Simeon-Rudolf V, Reiner E, Taylor P. Acetylcholinesterase active centre and gorge conformations analyzed by combinatorial mutations and enantiomeric phosphonates. Biochem J. 2003;373:33–40. PubMed PMC